-177-

- 7. The method of Claim 1 wherein the antineoplastic agent is Cell Pathways CP-461.
- 8. The method of Claim 1 wherein the antineoplastic agent is docetaxel.
- 5 9. The method of Claim 1 wherein the antineoplastic agent is doxorubicin.
 - 10. The method of Claim 1 wherein the antineoplastic agent is etoposide.
- 11. The method of Claim 1 wherein the 10 antineoplastic agent is fluoxymestrine.
 - 12. The method of Claim 1 wherein the antineoplastic agent is gemcitabine.
 - 13. The method of Claim 1 wherein the antineoplastic agent is goserelin.
- 15 14. The method of Claim 1 wherein the antineoplastic agent is irinotecan.
 - 15. The method of Claim 1 wherein the antineoplastic agent is ketoconazole.
- 16. The method of Claim 1 wherein the 20 antineoplastic agent is letrozol.
 - 17. The method of Claim 1 wherein the antineoplastic agent is leucovorin.
 - 18. The method of Claim 1 wherein the antineoplastic agent is levamisole.
- 25 19. The method of Claim 1 wherein the antineoplastic agent is megestrol.
 - 20. The method of Claim 1 wherein the antineoplastic agent is mitoxantrone.
- 21. The method of Claim 1 wherein the 30 antineoplastic agent is paclitaxel.

WO 00/38730 PCT/US99/30693

-178-

- 22. The method of Claim 1 wherein the antineoplastic agent is raloxifene.
- 23. The method of Claim 1 wherein the antineoplastic agent is retinoic acid.
- 5 24. The method of Claim 1 wherein the antineoplastic agent is tamoxifen.
 - 25. The method of Claim 1 wherein the antineoplastic agent is thiotepa.
- 26. The method of Claim 1 wherein the 10 antineoplastic agent is topotecan.
 - 27. The method of Claim 1 wherein the antineoplastic agent is toremifene.
 - 28. The method of Claim 1 wherein the antineoplastic agent is vinorelbine.
- 15 29. The method of Claim 1 wherein the antineoplastic agent is vinblastine.
 - 30. The method of Claim 1 wherein the antineoplastic agent is vincristine.
- 31. The method of Claim 1 wherein the antineoplastic agent is selenium (selenomethionine).
 - 32. The method of Claim 1 wherein the antineoplastic agent is sulindac sulfone.
 - 33. The method of Claim 1 wherein the antineoplastic agent is effornithine (DFMO).
- 25 34. The method of Claim 1 wherein the cyclooxygenase-2 inhibitor is selected from compounds, and their pharmaceutically acceptable salts thereof, of the group consisting of:

1)

$$H_2N$$
 F CH_3

JTE-522, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide,

5 2)

10

5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(methyl-5-pyridinyl)pyridine,

3)

2-(3,5-difluorophenyl)-3-4(methylsulfonyl)phenyl)-2-cyclopenten-1-one,

4)

4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide,